/s/    A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Sample Clauses

/s/    A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇. Director Director/Secretary Executed as a deed by CDT OXFORD LIMITED acting by ) /s/ S▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ) ) ) /s/ M▇▇▇▇▇▇ ▇▇▇▇▇ Director Director/Secretary Executed as a deed by A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ in the presence of ) ) /s/ A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ) Witness’ signature /s/ S▇▇▇▇▇ ▇▇▇▇▇▇ Name (print) S▇▇▇▇▇ ▇▇▇▇▇▇ Address 4▇▇ ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇ ▇▇▇. ▇▇ ▇▇▇ ▇▇▇▇, ▇▇ ▇▇▇▇▇ Occupation lawyer Executed as a deed by M▇▇▇▇▇▇ ▇▇▇▇▇▇ in the presence of ) ) /s/ M▇▇▇▇▇▇ ▇▇▇▇▇▇ ) Witness signature /s/ L▇▇▇▇▇ ▇▇▇▇▇▇ Name (print) L▇▇▇▇▇ ▇▇▇▇▇▇ Address 5▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇ ▇▇▇ Occupation Company director Executed as a deed by OPSYS US CORPORATION acting by ) /s/ M▇▇▇▇▇▇ ▇▇▇▇▇▇ ) ) ) /s/ A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Authorized Signatory Authorized Signatory Executed as a deed by OPSYS 2 CORPORATION acting by ) /s/ M▇▇▇▇▇▇ ▇▇▇▇▇▇ ) ) ) /s/ A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ Authorized Signatory Authorized Signatory GBP Accounts -7,634 -14,733.81 USD Accounts 16,303 16,303.00 Ashurst 53,797 103,828.21 B▇▇▇▇▇▇, D 12,428 23,986.04 L▇▇▇▇▇▇ ▇▇▇▇▇ Associates 4,389 8,470.77 Lingwood, R 113 218.09 M▇▇▇▇▇▇▇ & F▇▇▇▇▇▇▇ 22,540 22,540.00 Turnmell Ltd 4,700 9,071.00 Visian Ltd (J Bradford)* 16,097 31,067.21 OSCAR (P J▇▇▇▇▇▇) 8,000 15,440.00 Quester 32,400 62,532.00 M▇▇▇▇▇, D 5,000 9,650.00 Deloitte 9,000 17,370.00 Lingwood, R 1,808 3,489.44 Bradford, J 1,498 2,891.14 M▇▇▇▇▇, D 12,073 23,300.89 Ashursts as at 12/12* 101,000 194,930.00 Ashursts estimate to completion* 20,000 38,600.00 Contingency 10,000 19,300.00 General FX contingency 10,000 19,300.00 M. ▇▇▇▇▇ 0 0 * Amounts shown are exclusive of VAT which will need to be paid and can subsequently be reclaimed. Pentalpha Macau Offshore Limited $ 122,419 $ 122,419.00 Cash paid on completion 67,500 130,275.00 ** Employer’s NI thereon 8,640 16,675.20 Cash paid in instalments 95,000 183,350.00 ** Employer’s NI thereon 12,160 23,468.80 Payable in CDT Shares on completion 76,925 148,466.08 ** Employer’s NI thereon 9,846 19,003.66 Cash paid on completion 27,500 53,075.00 ** Employer’s NI thereon 3,520 6,793.60 Payable in CDT Shares on completion 136,046 262,569.71 ** Employer’s NI thereon 17,414 33,608.92 SUBTOTALS $ 161,262 £ 749,221 $ 1,606,102.00 TOTAL (in U.S. $) $ £ $ 1,606,102.00 ** Amounts are gross, U.K. income tax at rate of 40% will be withheld and employee’s National Insurance will be withheld. Arbitration: D▇▇▇▇▇▇ ▇▇▇▇▇ vs. Opsys Ltd., ICDR No. 50T-160-00473-03 Any claim against Opsys Limited arising as a result of or prior to the issuance of a final and non-appealable ...

Related to /s/    A▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇

  • Rejection During Probation ‌ (a) The Employer may reject any probationary employee for just cause. A rejection during probation shall not be considered a dismissal for the purpose of Clause 10.

  • Purchase Mechanism If the Focus Investor exercises its rights provided in this Section 4.5, the closing of the purchase of the New Securities with respect to which such right has been exercised shall take place within 30 calendar days after the giving of notice of such exercise, which period of time shall be extended for a maximum of 180 days in order to comply with applicable laws and regulations (including receipt of any applicable regulatory or corporate approvals). The Company and the Focus Investor agree to use commercially reasonable efforts to secure any regulatory or corporate approvals or other consents, and to comply with any law or regulation necessary in connection with the offer, sale and purchase of, such New Securities.

  • Black-Out Periods (a) Notwithstanding Section 2, and subject to the provisions of this Section 3, the Company shall be permitted, in limited circumstances, to suspend the use, from time to time, of the Prospectus that is part of a Shelf Registration Statement (and therefore suspend sales of the Registrable Securities under such Shelf Registration Statement), by providing written notice (a “Suspension Notice”) to the Selling Holders’ Counsel, if any, and the Holders, for such times as the Company reasonably may determine is necessary and advisable (but in no event for more than an aggregate of ninety (90) days in any rolling twelve (12)-month period commencing on the date of this Agreement or more than forty-five (45) consecutive days, except as a result of a refusal by the Commission to declare any post-effective amendment to the Shelf Registration Statement effective after the Company has used all reasonable best efforts to cause the post-effective amendment to be declared effective by the Commission, in which case, the Company must terminate the black-out period immediately following the effective date of the post-effective amendment) if either of the following events shall occur: (i) a majority of the Board determines in good faith that (A) the offer or sale of any Registrable Securities would materially impede, delay or interfere with any proposed financing, offer or sale of securities, acquisition, corporate reorganization or other material transaction involving the Company, (B) after the advice of counsel, the sale of Registrable Securities pursuant to the Shelf Registration Statement would require disclosure of non-public material information not otherwise required to be disclosed under applicable law, and (C) (x) the Company has a bona fide business purpose for preserving the confidentiality of such transaction, (y) disclosure would have a material adverse effect on the Company or the Company’s ability to consummate such transaction, or (z) such transaction renders the Company unable to comply with Commission requirements, in each case under circumstances that would make it impractical or inadvisable to cause the Shelf Registration Statement (or such filings) to become effective or to promptly amend or supplement the Shelf Registration Statement on a post-effective basis, as applicable; or (ii) a majority of the Board determines in good faith, upon the advice of counsel, that it is in the Company’s best interest or it is required by law, rule or regulation to supplement the Shelf Registration Statement or file a post-effective amendment to the Shelf Registration Statement in order to ensure that the Prospectus included in the Shelf Registration Statement (1) contains the information required under Section 10(a)(3) of the Securities Act; (2) discloses any facts or events arising after the effective date of the Shelf Registration Statement (or of the most recent post-effective amendment) that, individually or in the aggregate, represents a fundamental change in the information set forth therein; or (3) discloses any material information with respect to the plan of distribution that was not disclosed in the Shelf Registration Statement or any material change to such information. Upon the occurrence of any such suspension, the Company shall use its reasonable best efforts to cause the Shelf Registration Statement to become effective or to promptly amend or supplement the Shelf Registration Statement on a post-effective basis or to take such action as is necessary to make resumed use of the Shelf Registration Statement as soon as possible. (b) In the case of an event that causes the Company to suspend the use of a Shelf Registration Statement as set forth in paragraph (a) above (a “Suspension Event”), the Company shall give a Suspension Notice to the Selling Holders’ Counsel, if any, and the Holders to suspend sales of the Registrable Securities and such Suspension Notice shall state generally the basis for the notice and that such suspension shall continue only for so long as the Suspension Event or its effect is continuing and the Company is using its reasonable best efforts and taking all reasonable steps to terminate suspension of the use of the Shelf Registration Statement as promptly as possible. A Holder shall not effect any sales of the Registrable Securities pursuant to such Shelf Registration Statement (or such filings) at any time after it has received a Suspension Notice from the Company and prior to receipt of an End of Suspension Notice (as defined below). If so directed by the Company, each Holder will deliver to the Company (at the expense of the Company) all copies other than permanent file copies then in such Holder’s possession of the Prospectus covering the Registrable Securities at the time of receipt of the Suspension Notice. The Holders may recommence effecting sales of the Registrable Securities pursuant to the Shelf Registration Statement (or such filings) following further written notice to such effect (an “End of Suspension Notice”) from the Company, which End of Suspension Notice shall be given by the Company to the Holders and to the Selling Holders’ Counsel, if any, promptly following the conclusion of any Suspension Event and its effect. (c) Notwithstanding any provision herein to the contrary, if the Company shall give a Suspension Notice with respect to any Shelf Registration Statement pursuant to this Section 3, the Company agrees that it shall extend the period of time during which such Shelf Registration Statement shall be maintained effective pursuant to this Agreement by the number of days during the period from the date of receipt by the Holders of the Suspension Notice to and including the date of receipt by the Holders of the End of Suspension Notice and provide copies of the supplemented or amended Prospectus necessary to resume sales, with respect to each Suspension Event; provided that such period of time shall not be extended beyond the date that Common Stock covered by such Shelf Registration Statement are no longer Registrable Securities.

  • Optional Coverages If chosen by You, and shown as applicable on the Declarations Page, the following optional coverages apply separately to each Pet per Policy year. Some coverage options may be restricted by Pets age at time of sign-up. Defender/DefenderPlus We will reimburse You, if shown on the Declarations Page, for the Preventive Care listed below that Your Pet(s) receives from a licensed Veterinarian during the Policy period. Benefits will not exceed the Maximum Allowable Limits shown below. Coinsurance and Deductible requirements do not apply to Preventive Benefits. Our total liability of each Pet for each Policy Year is shown in the Maximum Allowable Limits. Spay/Neuter or Teeth Cleaning $0 $150 Rabies Vaccine $15 $15 Flea/Tick/Heartworm Prevention $80 $95 Vaccination/Titer $30 $40 Wellness Exam $50 $50 Heartworm test or FELV (Feline Leukemia Virus) screen $25 $30 Blood, fecal, parasite exam $50 $70 Microchip $20 $40 Urinalysis or ERD Test (Early Renal Disease Test) $15 $25 Deworming $20 $20 *Benefits may be combined or separate up to the maximum allowable limit. SupportPlus Coverage We will reimburse You, if shown on the Declarations Page, for the cost of final expenses for necropsy, cremation and urns upon the death of each Pet covered for such costs incurred after the Waiting Period and during the Coverage Period up to a maximum benefit of three hundred dollars ($300) subject to the Annual Limit amount. Coinsurance and Deductible provisions do not apply to SupportPlus Coverage. ExamPlus Coverage We will reimburse You, if shown on the Declarations Page, for the Covered Expenses that occur during the Coverage Period subject to Policy limits and exclusion including, but not limited to, Coinsurance, Deductible and Annual Limit for physical examination; including costs and/or fees for telephone consultation; to diagnose a current covered Injury. This endorsement does not provide coverage for annual wellness office exams.

  • RESERVE PRICE AND BIDDING AT AUCTION 1.1 This sale is made by AmBank (M) Berhad [196901000166 (8515-D)] (“Assignee/Bank”) in exercise of the rights and powers conferred upon the Assignee/Bank pursuant to the Composite Loan Agreement and Assignment and Power of Attorney both dated 02nd Day Of June, 2004executed by ▇▇▇▇ ▇▇▇▇ A/P VELOO(“Assignors/Borrowers”) in favour of the Assignee/Bank subject to all conditions and category of land use, express or implied or imposed upon or relating to or affecting the property (“Property”) and shall further subject to the reserve price (“Reserve Price”) and the Conditions of Sale as appearing in the Proclamation of Sale. 1.2 Subject to the provisions of Clause 5 below the highest bidder for the Property described in the Proclamation of Sale if so allowed by the Auctioneer shall be the Purchaser (“Purchaser”) thereof and the Auctioneer shall have the right to reject any bid. If any dispute shall arise as to any bidding, the Property shall be at the option of the Auctioneer be put up again for sale at the last undisputed bid or the Auctioneer may decide on the dispute and the decision of the Auctioneer on all matters not provided for in this Conditions of Sale shall be final and binding in all respects if such decision is made during the course of conducting the auction on the auction date. 1.3 No bid shall be less than the previous bid and each bid shall be increased by a minimum amount to be determined by the Auctioneer at the time the Property is put up for sale and no bidding shall be withdrawn or retracted. Should there be any withdrawal or retraction from the registered bidder(s) or the highest bidder before or after the fall of the hammer, the bidding deposit (“Bidding Deposit”) shall be forfeited to the Assignee/Bank and the Property shall be at the option of the Auctioneer be put up for sale again or the Auctioneer may decide to adjourn the auction sale to another date. 1.4 In the event the subject matter offered for auction comprises more than one (1) property, the Auctioneer shall have the right to: - (a) determine or vary the order of sale; (b) offer the properties for sale either individually or en bloc or in any combination/manner as determined by the Auctioneer; and/or (c) withdraw any of the properties from the sale.